Home    Back

Fludrocortisone    (DrugBank: Fludrocortisone)

3 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease2
17Multiple system atrophy1
81Congenital adrenal hyperplasia2

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,123 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01993680
(ClinicalTrials.gov)		June 201227/4/2012Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -TreatmentA Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson's DiseaseAutonomic Disturbances in Parkinson's DiseaseDrug: Pyridostigmine bromide;Drug: fludrocortisoneChristian BaumannNULLCompleted50 Years80 YearsAll18Phase 2Switzerland
2NCT00103597
(ClinicalTrials.gov)		January 200511/2/2005Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System AtrophyEfficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System AtrophyParkinson's Disease;Multiple System Atrophy;Orthostatic HypotensionDrug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic HypotensionRoyal Brisbane and Women's HospitalNULLCompleted40 Years95 YearsBoth50Phase 1Australia

17. Multiple system atrophy    [ 107 clinical trials,   153 drugs,   (DrugBank: 48 drugs),   59 drug target genes,   104 drug target pathways]
Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 107 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00103597
(ClinicalTrials.gov)		January 200511/2/2005Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System AtrophyEfficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System AtrophyParkinson's Disease;Multiple System Atrophy;Orthostatic HypotensionDrug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic HypotensionRoyal Brisbane and Women's HospitalNULLCompleted40 Years95 YearsBoth50Phase 1Australia

81. Congenital adrenal hyperplasia    [ 65 clinical trials,   77 drugs,   (DrugBank: 20 drugs),   11 drug target genes,   65 drug target pathways]
Searched query = "Congenital adrenal hyperplasia", "Congenital adrenal enzyme deficiency", "Congenial adrenal cortex enzyme deficiency", "Congenital Lipoid Adrenal Hyperplasia", "3β-Hydroxysteroid Dehydrogenase Deficiency", "21-Hydroxylase deficiency", "11β-Hydroxylase deficiency", "17α-Hydroxylase deficiency", "P450 oxidoreductase deficiency", "Aldosterone synthase deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 65 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03548246
(ClinicalTrials.gov)		January 202224/4/2015Androgen Reduction in Congenital Adrenal HyperplasiaA Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase DeficiencyCongenital Adrenal HyperplasiaDrug: Abiraterone acetate;Drug: Placebo;Drug: Hydrocortisone;Drug: FludrocortisoneUniversity of Texas Southwestern Medical CenterNational Institutes of Health Clinical Center (CC);University of Michigan;Children's Hospital Los Angeles;Feinstein Institute for Medical ResearchNot yet recruiting2 Years9 YearsAll54Phase 2United States
2NCT00001521
(ClinicalTrials.gov)		June 8, 19953/11/1999Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal HyperplasiaAn Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal HyperplasiaCongenital Adrenal Hyperplasia (CAH)Drug: Flutamide;Drug: Letrozole;Drug: Hydrocortisone;Drug: FludrocortisoneEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NULLActive, not recruiting2 Years18 YearsAll62Phase 2United States

Back to top